86 results about "Insulin dependence" patented technology

The present invention relates to compounds that are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.

The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE).

The invention belongs to the technical filed of medicines, and concretely relates to optically pure benzyl-4-chlorophenyl C-glucoside derivatives represented by formula (II) and formula (III), a method for preparing the above compounds and intermediates thereof, a medicinal preparation and a medicinal composition containing the compounds, and an application of the optically pure benzyl-4-chlorophenyl C-glucoside derivatives in the preparation of medicines for treating and / or preventing insulin-dependent diabetes, non-insulin dependent diabetes, insulin resistance diseases or obesity, various diabetes and relevant diseases as a sodium-glucose cotransporter (SGLT) inhibitor.

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

The object of the present invention is to provide a method of preparing excellent cultured muscle cells having high metabolic capacity and insulin responsiveness, and further provide a method for the measurement of sensitive metabolic capacity using the cells. Moreover, its purpose is to provide a culture system / culture apparatus that can smoothly translocate such highly advanced cultured muscle cells intact to activity evaluation systems of a number of drugs. Moreover, the object of the present invention is to provide cultured muscle cells that are very suitable for measurement of the membrane-translocation activity of GLUT4 in an extraneous stimulus-dependent manner such as insulin, etc., and to provide a method for the measurement of the membrane-translocation activity of GLUT4 using the cells. The present invention is a method of preparing myotube cells, comprising a step (1) of culturing myoblast cells, a step (2) of differentiation-inducing the myotube cells into the myoblast cells in a culture medium with a high content of amino acids, and a step (3) of applying an electric pulse to the differentiation-induced myotube cells, and a method for the measurement of insulin-dependent sugar uptake using the myotube cells prepared by said method, and relates to the method for the measurement, comprising applying insulin stimulation by culturing the cells in a culture medium containing insulin, culturing the cells in the culture medium further supplemented with sugar, and measuring the sugar uptake. Furthermore, the present invention relates to a differentiation-type culture myotube cell constitutively expressing a recombinant GLUT4 having a labeled substance at its extra-cellular site, which is prepared by co-culturing wild-type myoblast cells and recombinant myoblast cells constitutively expressing said recombinant GLUT4, and a method for the measurement of membrane-translocation activity of the recombinant GLUT4 using the cells, and particularly a method for the measurement of insulin-dependent sugar uptake activity.

The invention belongs to the field of medical technology, and particularly relates to a glucoside derivate shown as a formula (I), and a medically acceptable salt, an ester easily hydrolyzed, a stereoisomer and an itnemrediate of the glucoside derivate, and a preparation method of the compounds and the intermediate, in particular to a glucoside derivate which is served as a sodium-glucose co-transporter (SGLT) inhibitor, a medically acceptable salt, an ester easily hydrolyzed, a stereoisomer and an itnemrediate of the glucoside derivate, and a preparation method of the compounds and the intermediate. The glucoside derivate provided by the invention can be used for treating diabetes mellitus such as insulin dependent diabetes mellitus (I type diabetes mellitus) and non-insulin dependent diabetes mellitus (II type diabetes mellitus), and also can be applied to treating insulin resistance diseases and various diseases relevant to diabetes mellitus of fat, and preventing such diseases, wherein R1, R2, R3, R4, R5, R6, R7, R7a, R7b, R7c, X, n and A are defined as shown in the specification.

The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, and other diseases and conditions that are mediated by excessive glucocorticoid action.

There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.

The present invention relates to a process for isolating plant Argyrobium roseum extract that contains flavonoid glycoside, wherein the extract possesses hypoglycaemic activity. The present invention also contemplates a composition containing the extract and a method of treating various hyperglycaemic conditions including non-insulin dependent diabetes mellitus disease condition by administering the extract.

There are disclosed derivatives of 3-chromancarboxylic acid represented by formula Itheir pharmaceutically acceptable salts thereof and prodrugs thereof which are useful for treatment and control of non-insulin dependent diabetes mellitus (type II diabetes) and its related vascular disease as well as obesity and lipid disorders.

The invention provides the immunomodulator with the free adjuvant having the function of preventing and curing the insulin-dependent diabetes mellitus. Aiming at the weak immunogenicity, the antigen epitope polypeptide gene (a length of antigen epitope p277 rooted from human HSP60) is associated repeatedly six times and inserted repeatedly into the backward position of the heat shock protein HSP65 gene rooted from the mycobacterium bovis, the fusing expression between the repeat series connecting antigen polyeptide and the HSP65 is realized. The produced fusing albumen did not need the adjuvant; the antigen polyeptide don't need be coupled with the carrier chemistry to the immunity. The fusing albumen can inspire the organism to produce the high titer aiming at p277 by means of the mucous membrane immunity, so the nosogeny of NOD chmice diabetic are depressed highly. The invention can prevent the 1 type and 1.5 type diabete characterized in depending on the insulin.

The present invention relates generally to the field of human genetics. Specifically, the present invention relates to methods and materials used to isolate and detect human diabetes mellitus predisposing gene, specifically the angiotensinogen (AGT) gene, some mutant alleles of which cause susceptibility to insulin-dependent diabetes mellitus (IDDM). More specifically, the invention relates to gernline mutations in the AGT gene and their use in the diagnosis of predisposition to diabetes. The invention also relates to the prophylaxis and / or therapy of diabetes associated with a mutation in the AGT gene. The invention further relates to the screening of drugs for diabetes therapy. Finally, the invention relates to the screening of the AGT gene for mutations, which are useful for diagnosing the predisposition to diabetes.

The invention belongs to the medical technology field, more particularly relates to a dipeptidase-IV depressor derivative as shown in the formula (I), salt thereof acceptable in pharmacy, or isomers thereof; wherein, Ar, X, Y, Z, R<1>, R<2> and R<3> are defined in the specification; the invention also relates to the preparation method of the compounds, the medicine combination containing the compounds and the application of the compounds for preparing medicines used for treating and / or preventing diabetes, non-insulin-dependent diabetes, high blood-sugar and insulin resistance.

The invention belongs to the technical field of medicine, and particularly relates to C-indican derivative as shown in general formula (I), the pharmaceutically acceptable salt of the C-indican derivative, the easily-hydrolyzed ester of the C-indican derivative, and the stereoisomer and the intermediate of the C-indican derivative. The invention specifically relates to the C-indican derivative taken as sodium-dependent glucose transporters (SGLT) inhibitor, the pharmaceutically acceptable salt of the C-indican derivative, the easily-hydrolyzed ester of the C-indican derivative, and the stereoisomer and the intermediate of the C-indican derivative. The C-indican derivative provided by the invention not only can be used for the diabetes mellitus such as the insulin dependent diabetes mellitus (I type diabetes mellitus), the non-insulin dependent diabetes mellitus (II type diabetes mellitus) and the like, but also can be used for the treatment and the prevention of various mellitus-related diseases such as the insulin-resistant disease and the fatness. R1, R2, R3, R4, R5, R6a, R6b, R6c, W, M, n and A are defined in the specification.

The invention belongs to the medicine technology field, which particularly relates to a new dipeptidase-IV inhibitor compound, the salt acceptable in pharmacy and the isomer thereof; wherein, the R<1>, R<2>, Ar, n, X or Y are defined in an introduction; The invention also relates to preparing methods of the compounds and the drug combination containing the compounds and the applications of the compounds in preparing the medicine for curing or preventing diabetes, non-insulin-dependent diabetes, hyperglycemia and insulin resistance.

The invention discloses a 2-pyrrolidine substitution-hydrocinnamoyl pyrrolidine derivant which is the compound in formula 1 or an acceptable salt thereof in pharmacy, wherein, R1 or R2 is respectively hydrogen, cyano-group, acidic group, ester group, acyl group, amide group or substitution amide group independently; the hexagram symbol stands for a chiral centre. The invention further discloses a method for preparing the compound and the application thereof for preparing or preventing noninsulin-dependent diabetes mellitus, adiposis, arthritis or other glucose tolerance abnormality diseases.

The invention provides a fusion protein of Exendin-4 and mutational human serum albumin and a preparation method of the fusion protein, belonging to the technical field of long-acting recombined fusion protein drugs. The invention relates to the fusion protein of Exendin-4 and human serum albumin (HSA) in which the 410-site is mutated to A (Ala alanine) from R (Arg arginine). The fusion protein comprises two polypeptide zones, wherein zone I is composed of two Exendin-4 repetitive sequences, and zone II is site-mutation human serum albumin (HSA); the zone I is directly connected with the N-terminal of the zone II by the C-terminal of the zone I without adding any connecting peptides therebetween; and the structure of the fusion protein is: (Exendin-4)2-HSA (R410A). Compared with Exendin-4 and (Exendin-4)2-HAS, (Exendin-4)2-HSA (R410A) fusion protein provided by the invention has the characteristic of longer-lasting effect in vivo, and can be used for preparing long-lasting preparation of non-insulin-dependent diabetes.

The invention pertains to the field of medical technology, particularly relating to a DPP-IV inhibitor with a sulfamido formamide piperazine structure shown in the general formula (I), pharmaceutically acceptable salt or an isomer thereof, wherein, R, R, R and Ar are defined as the instruction book; the invention also relates to a preparation method of the compounds, a pharmaceutical composition containing the compounds and applications of the compounds in the preparation of medicaments for treatment and / or prevention of diabetes, noninsulin-dependent diabetes, hyperglycemia, insulin resistance.

The present invention discloses a peach bamboo tea using fruit tree plant as main raw material. Its composition comprises dried peach fruit, dried peach leaf, dried peach flower, dried tree root, bamboo leaf and green tea. Said invention can be used for directly curing diabetes (insulin dependence and chronic complicating disease), at the same time can be used for curing the diseases of hypertension, amenorrhea, constipation, senile dementia and cerebral thrombosis, etc. and can be used for regulating immunity of human body and activating immune interferon of human body self-body complement system to attain the goal of implementing synchronous health-care and therapy.

The invention belongs to the medicine technology field, which more particularly relates to a dipeptidase inhibitor compound, the salt acceptable in pharmacy and the isomer thereof shown in the formula (I); wherein, the R<1>, Ar, X, m and n are defined in an introduction; The invention also relates to preparing methods of the compounds, the drug combination containing the compounds and the applications of the compounds in preparing the medicine for curing or preventing diabetes, non-insulin-dependent diabetes, hyperglycemia and insulin resistance.

The invention belongs to the medicine technology field, which more particularly relates to a dipeptidase-IV inhibitor compound, the salt acceptable in pharmacy and the isomer thereof shown in the formula (I); wherein, the Ar, Ar', X, and R<1> are defined in an introduction; The invention also relates to preparing methods of the compounds, the drug combination containing the compounds and the applications of the compounds in preparing the medicine for curing or preventing diabetes, non-insulin-dependent diabetes, hyperglycemia and insulin resistance.

The present invention provides a compound represented by formula (I) in which an indole ring or a pyrrolo[2,3-b]pyridine ring and a pyrazolopyridine skeleton are bonded using a substituent, or a saltof the compound; solvates thereof; and prophylactic or therapeutic agents for non-insulin-dependent diabetes mellitus (type 2 diabetes mellitus), obesity, and the like in which said compound, salt, orsolvate is used as an active ingredient. (In the formula, X, Y, Q1, Q2, R1, R2, R3, R4, R5, R6, R7, R8, R9, n1, n2, Z1, and Z2 represent substances indicated in the present specification.)

The invention discloses a quinoline derivative or pharmacologically acceptable salt shown as a formula I (The formula is shown in the description), wherein R1, R2, R3 and R4 are respectively selectedfrom H or CH3. The compound listed in an in vitro DPP-4 enzyme inhibition test on the inhibition activity of DPP-4 is between Sitagliptin and omarigliptin. The quinoline derivative shown as the formula I disclosed by the invention is a DPP-4 inhibitor with a novel structure type, and the characteristics of the quinoline derivative in pharmacological toxicology and pharmacokinetics deserve more in-depth study, so that drugs used for treating and / or preventing non-insulin-dependent diabetes, hyperglycemia or insulin resistance can be obtained.

An orally taken solid medicine for treating the insulin independent diabetics is prepared from meguan, disintegrant, filler, swelling additive, flowing aid, and other medicinal auxiliary or carrier.

The invention provides a 4-piperazinemethyl-7-hydroxybenzofuran compound and medical application thereof, and relates to a compound and medical application thereof. The compound comprises the 4-piperazinemethyl-7-hydroxybenzofuran compound shown as a formula I as well as stereoisomers and pharmaceutically acceptable salts of the compound. The formula I is shown in the description, wherein Ar is independently selected from phenyl, C1-C4 alkyl-substituted phenyl, C1-C4 alkoxy-substituted phenyl, halogen-substituted phenyl and cyano-substituted phenyl. The compound provided by the invention can be applied to effective lipase inhibition medicines, is especially used as a novel nutrient absorption reducing agent, can act on gastrointestinal tract, is capable of inhibiting catalysis and decomposition of lipase and inhibiting absorption of part of fat from dietary intake, is applicable to obesity, and is suitable for obese people including healthy obese people and obese people with non-insulin-dependent diabetes mellitus.